Focus on XDEMVY's continued prescription growth trajectory and refill rate, which signal durable demand. The large IPR&D charges are one-time and non-cash; watch for pipeline catalysts in H1 2027 (TP-04 Phase 2, TP-05 Phase 2 results) and the Phase 3 start for IRX-101.
Drug in focus
TARS drug pipeline →ALK-001
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 NORTHSTAR trial succeeds, potential FDA approval would likely follow in 2030 or later, given topline data is not expected until H2 2029.
- Next catalyst
- None dated
What to watchALK-001 has no near-term binary catalyst, the Phase 3 NORTHSTAR topline readout is not expected until H2 2029. TARS stock will be driven primarily by XDEMVY commercial execution and nearer-term pipeline catalysts (TP-04, TP-05) over the next 12 months. Monitor the Alkeus acquisition close and any early NORTHSTAR enrollment updates, but do not trade TARS on ALK-001 expectations alone.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 4 $69.07entry
- T+1 · 12d ago −2.24%α +2.17% · $67.52
- T+5 · 6d ago +11.13%α +12.05% · $76.76
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tarsus reported Q3 2026 XDEMVY net product sales of $194.6M, up ~64% YoY and above the $190.8M consensus. However, the GAAP net loss widened to $668.3M ($14.40 per share) vs the $-1.77 consensus estimate, driven by $632.2M in acquired IPR&D expenses from the iRenix and Alkeus acquisitions. The underlying commercial momentum is strong, but the large one-time charges make headline earnings uninformative.
Key Financial Metrics
Key Facts
- XDEMVY net product sales $194.6M in Q3 2026, up ~64% YoY from $118.7M
- Revenue of $194.6M beat consensus of $190.8M
- GAAP net loss per share $(14.40) vs consensus $(1.77), driven by $632.2M in acquired IPR&D expenses
- Gross margin remained consistent at ~93%
- Cash, cash equivalents and marketable securities $309.6M as of Sep 30, 2026
- Surpassed 1M bottles dispensed and $1B cumulative net product sales since launch
- Refills accounted for ~20% of XDEMVY prescriptions in Q3
- Appointed Neera Clase as Chief Commercial Officer
- Completed acquisitions of iRenix Medical (IRX-101) and Alkeus Pharmaceuticals (gildeuretinol)
Financial Impact
Revenue beat consensus by ~$3.8M (2.0%); GAAP EPS miss of $(14.40) vs $(1.77) due to $632.2M non-cash IPR&D charge
Risk Factors
- GAAP net loss of $668.3M in Q3 alone, though largely driven by non-cash acquisition accounting
- R&D and SG&A expenses rising sharply (R&D $44.2M vs $16.3M, SG&A $168.0M vs $108.6M YoY)
- Pipeline programs (TP-04, TP-05, IRX-101, gildeuretinol) are early-stage with no near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3394778 |
Track record
21 reports on TARS
5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
- Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Viewing Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers